The cenobamate KORK study—A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add‐on lacosamide, perampanel, and brivaracetam

Documenti analoghi

• Effectiveness of adjunctive low‐dose clobazam in adults with focal drug‐resistant epilepsy and incomplete response to cenobamate: A real‐world study
  di: Ilaria Ciullo, et al.
  Pubblicazione: (2026)
• Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
  di: Han Wang, et al.
  Pubblicazione: (2025)
• Effectiveness of perampanel as the only adjunctive anti‐seizure medication in adults: Final results from the observational PERPRISE study in Germany
  di: Bernhard J. Steinhoff, et al.
  Pubblicazione: (2025)
• Impact of cenobamate on cortical responses to transcranial magnetic stimulation in people with drug‐resistant focal epilepsy
  di: Silvano R. Gefferie, et al.
  Pubblicazione: (2026)
• A VAMS‐based LC–MS/MS method for precise cenobamate quantification in epilepsy (patients)
  di: Federica Pigliasco, et al.
  Pubblicazione: (2024)